Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?
about
Differential gene expression by oxyphil and chief cells of human parathyroid glandsCinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs.Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism.Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidismCalcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges.Cinacalcet and Clinical Outcomes in Dialysis.Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism.Vitamin D receptor genetic variants among patients with end-stage renal disease.Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.Cinacalcet induces apoptosis in parathyroid cells in patients with secondary hyperparathyroidism: histological and cytological analyses.Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
P2860
Q34274874-50873DF6-3712-4C1A-A1B6-EAC0AEF5CE1DQ34362759-318010B7-CAED-4F97-8220-939DF042888BQ35026640-4BFAE89A-7AA2-446D-B9B0-8227B8F71638Q36906034-D4F77772-BB55-4A21-BD10-B3EE0D79B38AQ37102086-5D19CB77-CB92-4180-8FE8-0CC1E8FFE3BAQ37310824-C4837516-4E89-4F9D-A165-962790E8AB98Q37807991-3464955B-6549-4CE7-910D-78B04E4C7AAFQ38565049-9F4DAC5F-D498-4A24-86DB-F97B56528252Q40318370-AEC96A53-C2A9-49E8-B07C-479F3D265DE2Q42932772-284EB35F-F576-42B0-A56B-2A58833B64BDQ50034239-B4E1B712-96E8-49DE-AE59-6BCBC42EB311Q53067680-BF3FACA6-7B99-4FDC-8508-A3E2C0E6C7B9Q53551519-0CA4FA1D-C4B3-479B-A8C8-89A967FD819A
P2860
Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Does vitamin D receptor and ca ...... ry uremic hyperparathyroidism?
@ast
Does vitamin D receptor and ca ...... ry uremic hyperparathyroidism?
@en
type
label
Does vitamin D receptor and ca ...... ry uremic hyperparathyroidism?
@ast
Does vitamin D receptor and ca ...... ry uremic hyperparathyroidism?
@en
prefLabel
Does vitamin D receptor and ca ...... ry uremic hyperparathyroidism?
@ast
Does vitamin D receptor and ca ...... ry uremic hyperparathyroidism?
@en
P2093
P2860
P356
P1476
Does vitamin D receptor and ca ...... ry uremic hyperparathyroidism?
@en
P2093
Andrea Bruno
Annalisa Teutonico
Carlo Basile
Carlo Lomonte
Domenico Chimienti
Francesco Cazzato
Luigi Vernaglione
Savino Cocola
P2860
P304
P356
10.2215/CJN.04150907
P577
2008-03-05T00:00:00Z